A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C.
Latest Information Update: 15 Mar 2011
Price :
$35 *
At a glance
- Drugs VX 985 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 08 Mar 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 08 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.